Cantargia AB (FRA:7V3) Total Tax Payable : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Total Tax Payable?

Cantargia AB's Total Tax Payable for the quarter that ended in Sep. 2024 was €0.00 Mil.

Cantargia AB's annual Total Tax Payable declined from Dec. 2021 (€0.06 Mil) to Dec. 2022 (€0.03 Mil) and declined from Dec. 2022 (€0.03 Mil) to Dec. 2023 (€0.00 Mil).

Cantargia AB Total Tax Payable Historical Data

The historical data trend for Cantargia AB's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Total Tax Payable Chart

Cantargia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

0.01

0.03

0.06

0.03

Cantargia AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

Cantargia AB Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Cantargia AB Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

CANTA:Sweden

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.cantargia.com

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines